Identification of cysteine-rich epidermal growth factor-like domain 1α (CRELD1 α) as a novel α1A-adrenoceptor-down-regulating protein and establishment of an α1L-adrenoceptor-expressing cell line

Journal of Pharmacological Sciences

Volumn 113, Issue 2, 2010, Pages 169-181

  Nishimune, Atsushi ^a   Suzuki, Fumiko ^a   Yoshiki, Hatsumi ^a   Morishima, Shigeru ^a   Muramatsu, Ikunobu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

(CRELD1 ); Cysteine rich epidermal growth factor like domain 1 ; Phenotype pharmacology

Indexed keywords

2 [(5 CHLORO 3 ISOPROPYL 2 METHYLPHENYL)METHYL] 4,5 DIHDRO 1H IMIDAZOLE; 5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; 5 METHYLURAPIDIL; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; COMPLEMENTARY DNA; CYSTEINE RICH EPIDERMAL GROWTH FACTOR LIKE DOMAIN 1ALPHA; DABUZALGRON; MK 017; PHENTOLAMINE; PRAZOSIN; REGULATOR PROTEIN; SILODOSIN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; CRELD1 PROTEIN, HUMAN; SCLEROPROTEIN;

AGONIST; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; LIGAND BINDING; MALE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; ANIMAL; CHO CELL LINE; CRICETULUS; HAMSTER; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL ADHESION MOLECULES; CHO CELLS; CRICETINAE; CRICETULUS; DOWN-REGULATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 77953814683     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10093FP     Document Type: Article

References (53)

1. Alexander SP, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol. 2008;153 Suppl 2: S1-S209.
2. Lomasney JW, Cotecchia S, Lefkowitz RJ, Caron MG. Molecular biology of alpha-adrenergic receptors: implications for receptor classification and for structure-function relationships. Biochim Biophys Acta. 1991;1095:127-139.
3. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, et al. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev. 1995;47:267-270.
4. Zhong H, Minneman KP. Alpha1-adrenoceptor subtypes. Eur J Pharmacol. 1999;375:261-276.
5. Michelotti GA, Price DT, Schwinn DA. Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther. 2000;88:281-309.
6. Flavahan NA, Vanhoutte PM. Alpha-1 and alpha-2 adrenoceptor: response coupling in canine saphenous and femoral veins. J Pharmacol Exp Ther. 1986;238:131-138.
7. Muramatsu I, Ohmura T, Kigoshi S, Hashimoto S, Oshita M. Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle. Br J Pharmacol. 1990;99:197-201.
8. Muramatsu I, Suzuki F, Nishimune A, Anisuzzaman AS, Yoshiki H, Su TH, et al. Expression of distinct alpha1-adrenoceptor phenotypes in the iris of pigmented and albino rabbits. Br J Pharmacol. 2009;158:354-360.
9. Ford AP, Arredondo NF, Blue DR Jr, Bonhaus DW, Jasper J, Kava MS, et al. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy) ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol. 1996;49:209-215.
10. Stam WB, Van der Graaf PH, Saxena PR. Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery. Br J Pharmacol. 1999;127:661-670.
11. Argyle SA, McGrath JC. An alpha(1A)/alpha(1L)-adrenoceptor mediates contraction of canine subcutaneous resistance arteries. J Pharmacol Exp Ther. 2000;295:627-633.
12. Muramatsu I, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman AS, Tanaka T, et al. Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout. Br J Pharmacol. 2008;155:1224-1234.
13. Gray K, Short J, Ventura S. The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol. 2008;155:103-109.
14. Nishimune A, Suzuki F, Yoshiki H, Morishima S, Muramatsu I. alpha-Adrenoceptor pharmacome: alpha-Adrenoceptor and alpha-adrenoceptor in the lower urinary tract. Int J Urol. 2010:31-37.
15. Ramsay D, Carr IC, Pediani J, Lopez-Gimenez JF, Thurlow R, Fidock M, et al. High-affinity interactions between human alpha1A-adrenoceptor C-terminal splice variants produce homoand heterodimers but do not generate the alpha1L-adrenoceptor. Mol Pharmacol. 2004;66:228-239.
16. Suzuki F, Taniguchi T, Takauji R, Murata S, Muramatsu I. Splice isoforms of alpha(1a)-adrenoceptor in rabbit. Br J Pharmacol. 2000;129:1569-1576.
17. Hiraizumi-Hiraoka Y, Tanaka T, Yamamoto H, Suzuki F, Muramatsu I. Identification of alpha-1L adrenoceptor in rabbit ear artery. J Pharmacol Exp Ther. 2004;310:995-1002.
18. Morishima S, Tanaka T, Yamamoto H, Suzuki F, Akino H, Yokoyama O, et al. Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. J Urol. 2007;177:377-381.
19. Morishima S, Suzuki F, Yoshiki H, Md Anisuzzaman AS, Sathi ZS, Tanaka T, et al. Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1Land alpha1A-adrenoceptors. Br J Pharmacol. 2008;153:1485-1494.
20. Su TH, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman AS, Tanaka T, et al. Native profiles of alpha(1A)-adrenoceptor phenotypes in rabbit prostate. Br J Pharmacol. 2008;155:906-912.
21. Muramatsu I, Tanaka T, Suzuki F, Li Z, Hiraizumi-Hiraoka Y, Anisuzzaman AS, et al. Quantifying receptor properties: the tissue segment binding method - a powerful tool for the pharmacome analysis of native receptors. J Pharmacol Sci. 2005;98:331-339.
22. Nelson C. The alpha1L-adrenoceptor is an alternative phenotype of the alpha1A-adrenoceptor. Br J Pharmacol. 2008;155:1-3.
23. Jacobs S, Cuatrecasas P. The mobile receptor hypothesis and "cooperativity" of hormone binding. Application to insulin. Biochim Biophys Acta. 1976;433:482-495.
24. Piascik MT, Perez DM. Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther. 2001;298:403-410.
25. Suzuki F, Nishimune A, Yoshiki H, Morishima S, Muramatsu I. Alpha 1L-adrenoceptor phenotype revealed through the coexpression of alpha 1A-adrenoceptor and its novel interacting protein, ARIP. J Pharmacol Sci. 2010;112 Suppl 1:125P.
26. Suzuki F, Morishima S, Tanaka T, Muramatsu I. Snapin, a new regulator of receptor signaling, augments alpha1A-adrenoceptoroperated calcium influx through TRPC6. J Biol Chem. 2007;282:29563-29573.
27. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440-3450.
28. Lachnit WG, Tran AM, Clarke DE, Ford AP. Pharmacological characterization of an alpha 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat. Br J Pharmacol. 1997;120:819-826.
29. Furchgott RF. The classification on adrenoceptors (adrenergic receptors): an evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E, editors. Handbuch der experimentellen Pharmakologie. New York: Springer;1972. p. 283-335.
30. Muramatsu I, Murata S, Isaka M, Piao HL, Zhu J, Suzuki F, et al. Alpha1-adrenoceptor subtypes and two receptor systems in vascular tissues. Life Sci. 1998;62:1461-1465.
31. Rupp PA, Fouad GT, Egelston CA, Reifsteck CA, Olson SB, Knosp WM, et al. Identification, genomic organization and mRNA expression of CRELD1, the founding member of a unique family of matricellular proteins. Gene. 2002;293:47-57.
32. Takasaki J, Saito T, Taniguchi M, Kawasaki T, Moritani Y, Hayashi K, et al. A novel Galphaq/11-selective inhibitor. J Biol Chem. 2004;279:47438-47445.
33. Kenakin TP. Tissue response as a functional discriminator of receptor heterogeneity: effects of mixed receptor populations on Schild regressions. Mol Pharmacol. 1992;41:699-707.
34. Blue DR, Daniels DV, Gever JR, Jett MF, O'Yang C, Tang HM, et al. Pharmacological characteristics of Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence. BJU Int. 2004;93:162-170.
35. Taki N, Tanaka T, Zhang L, Suzuki F, Israilova M, Taniguchi T, et al. Alpha-1D adrenoceptors are involved in reserpine-induced supersensitivity of rat tail artery. Br J Pharmacol. 2004;142:647-656.
36. Rokosh DG, Simpson PC. Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci U S A. 2002;99:9474-9479.
37. Hiraoka Y, Ohmura T, Oshita M, Watanabe Y, Morikawa K, Nagata O, et al. Binding and functional characterization of alpha1- adrenoceptor subtypes in the rat prostate. Eur J Pharmacol. 1999;366:119-126.
38. Taniguchi T, Inagaki R, Murata S, Akiba I, Muramatsu I. Microphysiometric analysis of human alpha1a-adrenoceptor expressed in Chinese hamster ovary cells. Br J Pharmacol. 1999;127:962-968.
39. Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980;107:220-239.
40. Ford AP, Daniels DV, Chang DJ, Gever JR, Jasper JR, Lesnick JD, et al. Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification. Br J Pharmacol. 1997;121:1127-1135.
41. Daniels DV, Gever JR, Jasper JR, Kava MS, Lesnick JD, Meloy TD, et al. Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies. Eur J Pharmacol. 1999;370:337-343.
42. Testa R, Guarneri L, Angelico P, Poggesi E, Taddei C, Sironi G, et al. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. J Pharmacol Exp Ther. 1997;281:1284-1293.
43. Van der Graaf PH, Deplanne V, Duquenne C, Angel I. Analysis of alpha1-adrenoceptors in rabbit lower urinary tract and mesenteric artery. Eur J Pharmacol. 1997;327:25-32.
44. Pediani JD, MacKenzie JF, Heeley RP, Daly CJ, McGrath JC. Single-cell recombinant pharmacology: bovine alpha(1a)-adrenoceptors in rat-1 fibroblasts release intracellular Ca(2+), display subtype-characteristic agonism and antagonism, and exhibit an antagonist-reversible inverse concentration-response phase. J Pharmacol Exp Ther. 2000;293:887-895.
45. Methven L, Simpson PC, McGrath JC. Alpha1A/B-knockout mice explain the native alpha1D-adrenoceptor's role in vasoconstriction and show that its location is independent of the other alpha1-subtypes. Br J Pharmacol. 2009;158:1663-1675.
46. Leonardi A, Hieble JP, Guarneri L, Naselsky DP, Poggesi E, Sironi G, et al. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. J Pharmacol Exp Ther. 1997;281:1272-1283.
47. Taki N, Taniguchi T, Okada K, Moriyama N, Muramatsu I. Evidence for predominant mediation of alpha1-adrenoceptor in the tonus of entire urethra of women. J Urol. 1999;162:1829-1832.
48. Brady AE, Limbird LE. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal. 2002;14:297-309.
49. Bockaert J, Fagni L, Dumuis A, Marin P. GPCR interacting proteins (GIP). Pharmacol Ther. 2004;103:203-221.
50. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308:512-517.
51. Wang H, Westin L, Nong Y, Birnbaum S, Bendor J, Brismar H, et al. Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling. Science. 2009;326:1554-1557.
52. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393:333-339.
53. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54:233-246.